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Abstract
Background—The selection of the most appropriate treatment combinations requires the 
balancing of benefits and harms of these treatment options as well as the patients’ preferences for 
the resulting outcomes.
Objective—This research aimed at estimating and comparing the utility weights between elderly 
women with early stage hormone receptor positive (HR+) breast cancer receiving a combination of 
radiotherapy and hormonal therapy after breast conserving surgery (BCS) and those receiving a 
combination of BCS and hormonal therapy.
Methods—The Surveillance, Epidemiology, and End Results (SEER) linked with Medicare 
Health Outcomes Survey (MHOS) was used as the data source. Health utility weights were 
derived from the VR-12 health-related quality of life instrument using a mapping algorithm. 
Descriptive statistics of the sample were provided. Two sample t-tests were performed to 
determine potential differences in mean health utility weights between the two groups after 
propensity score matching.
Results—The average age at diagnosis was 72 vs. 76 years for the treated and the untreated 
groups, respectively. The results showed an inverse relationship between the receipt of 
radiotherapy and age. Patients who received radiotherapy had, on average, a higher health utility 
weight (0.70; SD = 0.123) compared with those who did not receive radiotherapy (0.676; SD = 
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0.130). Only treated patients who had more than two comorbid conditions had significantly higher 
health utility weights compared with patients who were not treated.
Conclusions—The mean health utility weights estimated for the radiotherapy and no 
radiotherapy groups can be used to inform a comparative cost-effectiveness analysis of the 
treatment options. However, the results of this study may not be generalizable to those who are 
outside a managed care plan because MHOS data is collected on managed care beneficiaries.
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Introduction
Breast cancer is the most commonly diagnosed cancer among women and it is projected that 
one in eight women will develop breast cancer in her lifetime1. Fifty percent of breast 
cancers are diagnosed at aged 61 and approximately 41% of breast cancers occur in women 
aged 652.
Treatment options for early stage breast cancer often include some combination of surgery, 
radiation, chemotherapy, and hormonal therapy and/or targeted therapy3. That being said, the 
selection of optimal treatment depends on balancing the benefits and harms of these 
treatment options as well as the preferences patients might have for the resulting outcomes. 
Compared with no radiation therapy after breast conserving surgery (BCS) for early stage 
breast cancer, radiation therapy has been associated with improved survival and has reduced 
the risk of recurrence. However, there is no clear evidence as to whether elderly patients 
with early stage hormone receptor positive (HR+) should or not receive radiation therapy 
after breast conserving surgery (BCS). On one hand, the results from randomized controlled 
trials suggest that the addition of radiation therapy after BCS does not improve the survival 
benefit for patients with less aggressive early stage breast cancer compared with those who 
were treated with hormonal therapy alone after BCS4–8. On the other hand, observational 
studies that reported the addition of radiation therapy after BCS had shown that the risk of 
death is reduced compared with no radiation and suggested the consideration of radiation 
therapy9,10.
The lack of clear evidence regarding the survival benefits of radiotherapy after BCS in 
elderly patients suffering from early stage HR + breast cancer poses challenges for optimal 
shared decision-making. Complete evidence regarding real-life survival benefits, quality of 
life, and costs associated with the addition or omission of radiotherapy to BCS and hormonal 
therapy are key to facilitate such a decision-making problem.
The focus of this study is on estimating and comparing the mean health utility weights for 
elderly patients presenting with early stage HR + breast cancer who were treated with a 
combination of radiotherapy and hormonal therapy after BCS versus those receiving 
hormonal therapy alone after BCS.
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Methods
Dataset
The Surveillance, Epidemiology, and End Results (SEER) – Medicare Health Outcomes 
Survey (MHOS) was used. The data provides individual patient demographics, clinical, and 
cause of death information from nationwide registries and patient reported outcomes of 
elderly patients who are enrolled in Medicare advantage organizations (managed care health 
plans). The collection of patient reported outcomes data, by Centers for Medicare & 
Medicaid Services (CMS), started since 1998. The purpose of the survey is a Medicare 
Advantage quality improvement initiative to provide health status information to consumers, 
beneficiaries and health plans11. Since then, multiple cohorts have been recruited (14 
cohorts), covering data for the years 1998 to 2013. The cohorts include patients with and 
without cancer. The SEER-MHOS dataset provides HRQOL information measured via Short 
Form-36 (SF-36) until 2005 and Veteran Rand-12 (VR-12) starting 200612. A baseline 
survey is administered every year to a new cohort. Each cohort is resurveyed two years after 
baseline to provide two waves of data. Ambs and colleagues provided details about the 
SEER-MHOS dataset12.
Patient population
The patient population was composed of elderly women diagnosed with HR + early stage 
breast cancer. Those who received radiotherapy served as the treatment group while those 
did not receive radiotherapy were treated as the control group. Since MHOS changed the 
data collection instrument in 2006, the patient population was selected from six cohorts 
starting cohort 9 to 14 (2006 and 2008, 2007 and 2009, 2008 and 2010, 2009 and 2011, 2010 
and 2012, 2011 and 2013). The following inclusion and exclusion criteria were applied to 
obtain the study samples.
Inclusion criteria
• Patient diagnosed with breast cancer as a primary cancer.
• Patient diagnosed with early stage hormone receptor positive breast cancer. Stage 
of breast cancer was defined based on the American Joint Committee on Cancer 
(AJCC) staging criteria (early stage [stage 1 and 2] when T1–T3/N0, or M0).
• Patient lived in SEER area at the time of survey.
• Patient had undergone breast conserving surgery.
• Elderly patient (age 65 and older at the time of diagnosis).
• The first survey after the most recent breast cancer diagnoses for those who 
completed multiple surveys.
Exclusion criteria
• Patient was male.
• Patient surveyed before diagnosed.
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• Patient diagnosed with other cancer.
Cases with missing or unknown treatment status (surgery and/or radiation surgery 
sequence).
• Patient diagnosed with stage III and IV breast cancer and unknown stage status.
• Patient diagnosed with autopsy and death certificate.
• To minimize recall bias, patients diagnosed before the year 2004 were excluded 
in the analysis.
Duplicate cases were excluded by retaining the first case recorded. Between the years 2004 
to 2011, 754 elderly women were identified who were diagnosed with early stage hormone 
receptor breast cancer, received BCS alone or BCS plus radiation treatment and met the 
other pre-specified inclusion criteria. Among 754 patients, 562 received BCS plus radiation 
(BCS plus radiation plus hormonal therapy) and 192 of them received BCS alone (BCS + 
hormonal therapy). The data extraction process is summarized in Figure 1.
Variable identification and measurement
We controlled for socio-demographic (age, race/ethnicity, and marital status) factors, 
comorbidities, tumor grade, and tumor size. Age represented age at the time of diagnosis. 
Race (white, black, and others) was defined as the patient reported at the time of diagnosis. 
Marital status represented the marital status, which was a dichotomous variable indicating 
the marital status (married or not) of the women at the time of diagnosis. Patients’ education 
levels were identified from MHOS. Education is coded as follows: high school graduate or 
less, some college education, a 4 year college education, and more than 4 year education. 
Any chronic conditions that were reported by the patient were considered as comorbidities. 
The following comorbidities were reported by the patients: hypertension/high blood 
pressure, angina pectoris/coronary artery disease, congestive heart failure, myocardial 
infarction, other heart conditions, stroke, emphysema, asthma, or chronic obstructive 
pulmonary disease (COPD), Crohn’s ulcerative colitis or inflammatory bowel diseases 
(IBD), arthritis of hip/knee, arthritis of hand/wrist, sciatica, and diabetes. These 
comorbidities were collapsed into a categorical variable with three levels: no comorbidity, 
1–2 comorbidities, and >2 comorbidities. A proxy measure (yes/no) was yes if the survey 
was filled out by the third party. The tumor grade was identified from the SEER dataset. 
Tumor grade was a categorical variable coded as well differentiated, moderately 
differentiated, and combined poorly differentiated and undifferentiated. The definition and 
measurement of the variables used in this study are presented in Table 1.
Treatments
This study examined and compared the health utility of patients treated with radiation 
therapy (radiation plus hormonal) and no radiation therapy (hormonal therapy only) after 
breast conserving surgery. However, SEER data does not provide information regarding 
hormonal therapy. Since hormonal therapy is a recommended treatment for patients 
diagnosed with hormone receptor positive breast cancer, we assumed that hormonal therapy 
was administered if the patient was diagnosed with hormone receptor positive breast cancer.
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Surgical treatment is categorized as mastectomy or breast conserving surgery (BCS). BCS is 
defined as partial mastectomy with nipple resection, lumpectomy or excisional biopsy, re-
excision of the biopsy site for gross or microscopic residual disease and segmental 
mastectomy (including wedge resection, quadrantectomy, and tylectomy. Mastectomy is 
defined as a subcutaneous mastectomy, total (simple) mastectomy, bilateral mastectomy, 
modified radical mastectomy, and extended radical mastectomy.
The receipt of radiation therapy after BCS was a dichotomous variable: yes if the patient 
received radiation after surgery and no if the patient did not receive radiation therapy after 
surgery. This variable was constructed using the radiation surgery sequence and surgery 
information. Seven categories of radiation surgery sequence are available in the SEER 
dataset: no radiation and/or cancer directed surgery, radiation prior to surgery, radiation after 
surgery, radiation before and after surgery, intraoperative radiation, intraoperative radiation 
with and other radiation before/after surgery, and sequence unknown, but both were given. A 
patient was considered as having received radiation therapy after BCS if any of the 
following criteria were met: the woman has to receive BCS, radiation after surgery, radiation 
before and after surgery, and intraoperative radiation with and other radiation before/after 
surgery. If the patients received BCS but “no radiation and/or cancer directed surgery, 
radiation prior to surgery, and intraoperative radiation” then treatment was defined as BCS 
only. We included the cases where the treatment sequences were known.
Outcome measures
The outcome of interest in this study was health utility. We used a novel multi-stage 
mapping algorithm to convert VR-12 into VR-6D13 for the radiation therapy and no 
radiation therapy groups. The multi-stage mapping approach involves the use of different 
health-related quality of life (HRQOL) questionnaires (SF-36, VR-36 and VR-12) to derive 
preference-based measures (SF-6D and VR-6D).
SF-36, VR-36 and VR-12 questionnaires are composed of eight health dimensions, and 
these dimensions are physical functioning, role limitations due to physical health problems, 
bodily pain, general health, vitality (fatigue), social functioning, role limitations due to 
emotional problems, and mental health14. For each of the eight dimensions, these 
questionnaires generate a score on a 0–100 scale, 0 representing the worst health and 100 
representing perfect health14.
The SF-6D was derived from SF-36 with six dimensional wellbeing states to determine 
patients’ preferences for these states. The six dimensions are physical working, part 
restrictions, social working, agony, psychological well-being, and imperativeness13.
The VR-6D, a preference-based measure derived from the VR-12, has comparable 
distributional properties to the SF-6D13. The VR-6D represents health utility scores ranging 
between 0 and 1, 0 representing death and 1 representing optimal health13. The multi-stage 
mapping algorithm operates as follows13:
• Step 1: The prediction of SF-6D scores from responses to VR-36 questionnaire 
using the coefficient of the regression of the Brazier’s SF-6D scores onto the 
SF-36 questionnaire.
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• Step 2: The predicted SF-6D scores from responses to VR-36 were compared to 
the Brazier’s SF-6D scores. Some adjustments were made for the SF-6D scores 
from VR-36 to have a maximum utility value of 1.
• Step 3: The adjusted SF-6D scores from VR-36 were regressed on the non-native 
VR-12 questionnaire. Missing data and differences related to the structure of the 
non-native and native VR-12 as well as mode of administration of the 
questionnaire (phone or mail) were controlled for.
• Step 4: The estimation of VR-6D scores from VR-12 was based on steps 2 and 3.
Statistical analysis
The statistical analysis was performed according to the following steps using SAS 9.4 and 
Stata 14.0 statistical software. First, we computed descriptive statistics for the treatment and 
control groups (Table 2). Second, we matched the radiation therapy and no radiation therapy 
groups using propensity score. The rationale for using the propensity score is to mimic 
randomized controlled trials by ensuring that observed confounders in the dataset (listed in 
Table 2) are equally distributed between the radiation therapy and no radiation therapy 
groups. The application of propensity score matching consisted of estimating the probability 
of receiving treatment using Equation 1. To this aim, we used the pscore Stata command 
with logit option.
(1)
Treated and control groups were matched based on the probability of receiving treatment. 
The corresponding Stata command psmatch2 was used with the following specifications: the 
three nearest neighbors with replacement, tied observations, and common support condition. 
The balancing property of the covariates between the radiation and no radiation groups was 
checked graphically and analytically. The graphical test involved plotting and comparing the 
distributions of the propensity score for radiation and no radiation therapy groups before and 
after matching. In case the balancing property is satisfied, we would expect the distribution 
of propensity scores in the treated and untreated groups to superimpose after matching. In 
addition, a post-estimation test (pstest) was conducted to check for the mean equality of the 
propensity scores for the treated and untreated groups before and after matching. This test 
was further used to quantify the reduction of bias after matching.
Third, we compared the average (mean) health utility of patients who received radiation 
therapy to that of those who did not receive it after the matching procedure, using a two 
sample t-test. Institutional Review Board (IRB) exemption was granted from Florida 
Agricultural and Mechanical University.
Results
Patient characteristics before propensity matching
Only complete cases and those who underwent BCS were included in this analysis, meaning 
no data imputation rule was used for missing values except for the days of diagnosis and 
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treatment with known year and month. Since the SEER-MHOS data does not include the 
day of diagnosis and treatment, we imputed these dates as follows: the first of the month was 
considered as the day of diagnosis while the 28th day of the month was considered as the 
day of the initiation of treatment.
Among patients who met the inclusion criteria (754), 132 observations were excluded from 
further analyses due to unknown or missing covariates data (list of covariates in Table 2). As 
a result, 618 observations were retained for further analyses.
Most of the patients received BCS plus radiation 472 (76.38%). Overall, a large proportion 
of patients were white (79.94%), high school graduates or less (55.50%), diagnosed with 
moderately differentiated tumor grade (49.19%), and resided in a metro area (93.69%). The 
mean time from diagnosis to survey time was 27.31 (SD = 20.57) months and the mean 
waiting time between diagnoses to initial treatment was approximately 2 months. On 
average, patients who did not receive radiation were significantly older (76.64) than women 
who received radiation therapy after BCS (72.53). On one hand, the proportion of patients 
who did not receive radiation therapy after BCS increased from women diagnosed age 
between 65 and 69 (19.86%) to age 80 and above (35.62%). On the other hand, the 
likelihood of receiving radiation therapy decreases when women are diagnosed at older age. 
Detailed descriptive statistics are provided in Table 2.
Utility before propensity matching
The overall average health utility weight before the propensity score matching was 0.695 
(0.125 SD). Compared with patients who did not receive radiotherapy (0.673), women who 
received radiotherapy after BCS had significantly higher health utility (0.701; p = .0164), on 
average.
Assessment of the propensity score matching
The balancing property of propensity score matching was satisfied. As shown in Figure 2, 
the standardized percentage biased across the covariates was lower in the matched data 
compared to the unmatched data. Furthermore, the distribution of the propensity score 
before matching and after matching indicates that the propensity score approach creates 
balance over the covariates for the radiation group and BCS only group. In addition, Figures 
2 and 3 show that the balancing property of the matching is met. Figure 3 shows a non-
parametric density estimate of the distribution of the estimated propensity before and after 
matching for patients who received radiation therapy and those who did not receive radiation 
therapy after BCS separately. The mean and median bias for the unmatched data was 77.4 
whereas the mean and median bias for the matched data was 0.3. In general, the propensity 
score reduces the bias by 99.6%. This indicates that there is a greater likelihood that the 
covariates are balanced in both groups, after propensity score matching. Patients who did not 
receive radiation therapy tend to have lower propensity score before matching. After 
propensity score matching, both groups had approximately similar propensity score 
distributions. The mean propensity scores of the matched data for the radiation and no 
radiation groups are 0.78659 and 0.78616 respectively.
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Post-estimation
The propensity score matching generated 459 treated and 133 control patients. Table 3 
reports the estimated average utility by radiation and no radiation groups after the propensity 
score matching method. The Stata command “Psmach2” generates a weight variable, which 
had missing values for some observations that were not matched. The matched data were 
obtained after deleting observations that had missing weights. The average utility was 0.696 
(range 0.686 to 0.706). This finding suggests that there is a statistically significant difference 
between patients who were treated with radiation and those who were not treated with 
radiation therapy after BCS. Those who received radiation therapy had a higher average 
utility (0.701) compared to those who were not treated with radiation therapy (0.676) after 
BCS.
On the one hand, women who received radiotherapy after BCS and were aged between 65 
and 79 had a higher health utility. On the other hand, women who were not treated with 
radiation and were 80 years old and above had relatively higher health utility weight. This 
difference was not statistically significant. White elderly women treated with radiation 
therapy had significantly better health utility than white elderly women who were not treated 
with radiation therapy after BCS (0.704 versus 0.675).
Only treated patients who had more than two comorbid conditions had significantly higher 
health utility compared with women who were not treated after BCS. Patients who were 
initially treated within 2 months of breast cancer diagnosis, and then received radiotherapy, 
had significantly higher health utility (0.702) than those who were not (0.674).
Among patients who received radiotherapy, the treatment was predicted to non-significantly 
increase utility by 1.41% on average.
Discussion
This study aimed to estimate and compare the health utility associated with the use of 
radiotherapy in combination with hormonal therapy after BCS in elderly patients diagnosed 
with early stage hormone receptor positive breast cancer. To meet the objective of this 
research, we used a population-based cancer registry data linked with patient reported 
outcomes data. Propensity score matching was employed to overcome the limitations of 
observational studies regarding imbalance between the treated and control groups over 
observed covariates. In addition, it was expected that the application of propensity score 
matching would improve the internal validity of this study.
The findings of this study suggest that elderly patients who received radiotherapy had, on 
average, a higher health utility weight compared with those who were not treated with 
radiotherapy after BCS, although the effect of radiotherapy on health utility on those who 
received radiation therapy was not statistically significant. The insignificance of average 
treatment effect among the treated could be attributed to several factors including the small 
sample size and response heterogeneity and unmeasured confounders. Previous studies have 
investigated the impact of the addition of radiotherapy on the quality of life of older breast 
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cancer patients15–18. Overall, they reported similar quality of life between the treated and the 
control patients, although they varied in their designs, sample size, and participants’ age.
Even though there was no significant difference in health utility whether the patients were 
treated or not by age, we were able to observe that the health utility benefit of receiving 
radiotherapy waned as the patients were getting older. The inverse relationship of quality of 
life and the presence of comorbid conditions in cancer patients have been documented in 
previous studies19–22. Similar to these studies results, our study found that the health utility 
in both the treated and untreated groups declined as the number of comorbidities increases. 
Nevertheless, the decrease in health utility in those patients with comorbidities appeared to 
be worse in the untreated compared to the treated.
Patients who initiated their breast cancer treatment within 2 months of their diagnosis and 
had membership in the radiotherapy group have reported a higher health utility compared to 
the non-members. This may suggest that patients benefit more from receiving radiotherapy 
as compared to not receiving radiotherapy. The positive association between the health 
utility weight and early initiation of treatment could be explained by self-selection.
We observed that only white patients who were treated had significantly higher health utility 
than untreated patients. The relationship between race and treatment and the mechanisms 
through which they impact health utility are not clear and need further research.
This study has strengths and limitations. The main strength of this study relates to the 
minimization of selection bias by creating comparable treatment and control groups using 
propensity score matching. The adoption of propensity score matching allowed us to make 
causal inference. To our knowledge, this study is the first study that estimated and compared 
the health utility weights among elderly women with early stage HR + BC, receiving 
radiation therapy compared to those who did not receive radiation therapy.
Even though propensity score matching is a powerful tool to adjust for a large number of 
covariates, it can only adjust for observed covariates23. When unobserved or hidden biases 
exist, propensity score method does not account for them, resulting in biased estimates24. 
Second, the result of this study may not be generalizable to those who are out of managed 
care plan because MHOS data is collected on managed care beneficiaries. In addition, SEER 
does not collect data in areas where elderly patients reside (such as Florida). Therefore, the 
generalizability of this study to non-SEER areas may be limited. Third, cancer-specific 
HRQOL information may be important in order to make informed treatment decisions. 
However, MHOS data offers only the general HRQOL of the women. Fourth, SEER-MHOS 
data does not provide hormonal therapy information: we assumed that all women diagnosed 
with hormone receptor positive breast cancer received hormonal therapy. This assumption 
may overestimate the use of hormonal therapy.
Furthermore, misclassification of some variables including comorbidity may be an issue 
since the information collected was self-reported. The difference in the choice of treatment 
could be attributed to the patient’s physician and individual perceived benefit. Due to lack of 
data, we were not able to control for physicians’ influence on the selection of treatment and 
individual self-selection behavior.
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This study illustrates the need to explicitly consider other factors such as comorbidities in 
making decisions to treat elderly patients diagnosed with early stage hormone receptor 
positive breast cancer with radiotherapy. The estimated mean health utility weights for the 
treated and untreated groups can be used in a cost-effectiveness analysis of the treatment 
options assessed in this study to inform reimbursement policy decision-making.
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Figure 1. 
Summary of data extraction. Abbreviations. BC, breast cancer; BCS, breast conserving 
surgery.
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Figure 2. 
Standardized percentage bias across covariates for unmatched and matched data.
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Figure 3. 
Propensity score density graph for radiation and no radiation therapy groups before and after 
matching.
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Table 1
Variable definition and measurement used in the analysis.
Variable name Definition and measurement
VR-6D index A single utility index generated from VR-12
Radiation therapy 1 if the patient received radiation therapy after BCS,
  otherwise 0
Race 0 if the patient was white
1 if the patient was black
2 if the patient was not white nor black (others)
Marital status 0 if the patient was unmarried (single, divorced,
  and widowed)
1 if the patient was married
Age at diagnosis 0 if the patient age was 65–69 years
1 if the patient age was 70–74 years
2 if the patient age was 75–79 years
3 if the patient age was 80 years or older
Tumor grade 0 if the tumor was well differentiated
1 if the tumor was moderately differentiated
2 if the tumor was poorly differentiated or
  undifferentiated
Education 0 if the patient was high-school graduate or less
  (≤high school)
1 if the patient had some college degree or 2 years
  degree
2 if the patient was college graduate or higher
Comorbidity 0 if the patient had no comorbidity
1 if the patient had 1–2 comorbidities
2 if the patient had >2 comorbidities
Proxy If the survey was completed by a third party, i.e.
  not self-reported
0 if the survey was completed by the patient herself
1 if the survey was completed by a third party
Time from cancer
  diagnosis to survey
0 if time from cancer diagnosis was ≥0 months but
  <7 months
1 if time from cancer diagnosis was ≥7 months but
  <12 months
2 if time from cancer diagnosis was ≥13 months
  but <19 months
Time from diagnosis
  to treatment
0 if time from diagnosis to treatment <2 months
1 if time from diagnosis to treatment is ≥2 months
Area of residence 0 if the women reside in non-metro area at the
  time diagnosis
1 if the women reside in metro area at the time of
  diagnosis
Year of diagnosis The year the patient diagnosis breast cancer
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Table 2
Characteristics of the breast cancer original cohort by treatment type before propensity matching.
Characteristics Women with breast 
cancer
(N = 618)
Breast cancer cases by treatment type
No radiation
(N = 146; 23.62%)
Radiation
(N = 472; 76.38%)
p-value
Mean utility 0.695 (0.125) 0.673 0.701 .0164
Age in years, N (%) <.0001
Mean age at diagnosis, mean (SD) 73.72 (6.21) 76.64 (7.09) 72.53 (5.41) <.0001
  Between 65 and 69 193 (31.23) 29 (19.86) 164 (34.75)
  Between 70 and 74 192 (31.07) 35 (23.97) 157 (33.26)
  Between 75 and 79 120 (19.42) 30(20.55) 90 (19.07)
  80 and above 113 (18.28) 52 (35.62) 61 (12.92)
Race, N (%) .3974
  White 497 (79.94) 120 (82.19) 374 (79.24)
  Black 59 (9.55) 15 (10.27) 44 (9.32)
  Others 65 (10.52) 11 (7.53) 54 (11.44)
Marital status at baseline, N (%) .0034
  Married 311 (49.32) 58(39.75) 253 (53.60)
  Unmarried 307 (49.68) 88 (60.27) 307 (53.60)
Education, N (%) .327
  High school graduates or less (≤high school) 343 (55.50) 87 (59.59) 256 (54.24)
  Some college degree or 2 years degree 171 (27.67) 40 (27.40) 131 (27.75)
  College graduate or higher 104 (16.83) 19(13.01) 85 (18.38)
Area of residence .2778
  Metro area 579 (93.69) 134 (91.78) 445 (94.28)
  Non-metro area 39 (6.31) 12 (8.22) 27 (5.72)
Comorbidity, N (%) .4250
  Healthy (0 comorbidities) 62 (10.03) 12 (8.22) 50 (10.59)
  1–2 comorbidities 253 (40.94) 66 (45.21) 187 (39.62)
  >2 comorbidities 303 (49.03) 68 (46.58) 235 (49.79)
Grade, N (%) .8780
  Well differentiated 243 (39.32) 60 (41.10) 183 (38.77)
  Moderately differentiated 304 (49.19) 70 (47.95) 234 (49.58)
  Poorly differentiated and undifferentiated 71 (11.49) 16(10.96) 55 (11.65)
Proxy, N (%) .0184
  Yes 85 (13.75) 18(12.33) 30 (6.36)
  No 533 (86.25) 128 (87.67) 442 (93.64)
Survey time point, N (%)
  Baseline 492 (79.61) 112 (76.71) 380 (80.51) .3197
  Follow-up 126 (20.39) 34 (23.29) 92 (19.49)
Survey disposition, N (%) .4222
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Characteristics Women with breast 
cancer
(N = 618)
Breast cancer cases by treatment type
No radiation
(N = 146; 23.62%)
Radiation
(N = 472; 76.38%)
p-value
  Mailed survey 533 (56.25) 23 (15.75) 62 (13.14)
  Telephone survey 85 (13.75) 123 (84.25) 410 (86.86)
Time from cancer diagnosis to survey, mean (SD), months 27.31 (20.57) 25.32 (19.89) 27.93 (20.76) .1812
Time from cancer diagnosis to survey, N (%) .6227
  0–6 months 89 (14.40) 23 (15.75) 66 (13.98)
  7–12 months 78 (12.62) 20 (13.70) 58 (12.29)
  13–18 months 88 (14.24) 24 (16.44) 64 (13.56)
  19+ months 368 (58.74) 79 (54.11) 284 (60.17)
Time from diagnosis to treatment, Mean (SD), months 1.81 (1.00) 1.79 (1.40) 1.81 (0.84) .7799
Time from diagnosis to treatment, N (%) .8396
  <2 months 503 (81.39) 118(80.82) 385 (81.57)
  ≥2 months 115 (18.61) 28 (19.18) 87 (18.43)
Year of diagnosis .2458
  2004 76 (12.30) 13 (8.90) 63 (13.35)
  2005 80 (12.94) 16(10.96) 64 (13.56)
  2006 91 (14.72) 29 (19.86) 62 (13.14)
  2007 93 (15.05) 21 (14.38) 72 (15.25)
  2008 84 (13.59) 23 (15.75) 61 (12.92)
  2009 77 (12.46) 22 (15.06) 55 (11.65)
  2010 66 (10.68) 12 (8.22) 54 (11.44)
  2011 51 (8.25) 10 (6.85) 41 (8.69)
SD: standard deviation; N: number of observations; %: percent and column percent.
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